# Iovance Biotherapeutics market performance

> Live situation record from CLSTR: https://clstr.news/situations/iovance-biotherapeutics-market-performance
> Updated: 2026-09-29T13:55:58.000Z. Sources: 6. Developments: 2.

Iovance Biotherapeutics experienced significant stock growth driven by positive analyst sentiment and improved financial outlooks. Initially, shares reached a 52-week high following a Goldman Sachs upgrade to a ‘buy’ rating, with analysts citing the performance of the melanoma drug Amtagvi as a key driver.

This momentum continued as the company sharply increased its 2026 revenue forecast, raising guidance to between $410 million and $420 million from a previous range of $350 million to $370 million. This upward revision, representing nearly 60% annual growth, is attributed to accelerating demand for Amtagvi and Proleukin, alongside the expansion of authorized treatment centers, with a goal of reaching at least 110 centers by the end of the year.

Following the revenue guidance update, H.C. Wainwright maintained a ‘Buy’ rating and significantly raised its price target for the stock from $9 to $20.

## Timeline

### 2026-09-29: Iovance Biotherapeutics shares surge on raised 2026 revenue forecast

Iovance Biotherapeutics shares hit a two-year high after the company raised its 2026 revenue forecast to $410 million-$420 million, driven by high demand for its melanoma treatment, Amtagvi.

4 sources. https://clstr.news/cluster/iovance-biotherapeutics-shares-surge-on-raised-2026-revenue-forecast

### 2026-09-24: Iovance Biotherapeutics shares hit new high following analyst upgrade

Iovance Biotherapeutics shares hit a 52-week high after Goldman Sachs upgraded the stock to a buy, citing strong sales of its melanoma treatment, Amtagvi.

2 sources. https://clstr.news/cluster/iovance-biotherapeutics-shares-hit-new-high-following-analyst-upgrade

---
Cite as: Iovance Biotherapeutics market performance. CLSTR, https://clstr.news/situations/iovance-biotherapeutics-market-performance